Scilex Holding (SCLX) Gross Profit Margin starting from the second quarter 2026 to second quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Scilex Holding Company  (NASDAQ: SCLX)


Scilex Holding's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SCLX Gross Profit Margin (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3 		(Jun 30 2025)
Q2
Y / Y Revenue Change -22.78 %
Seq. Revenue Change -11.27 %
Revenue In Millions $7.64
Gross Profit Margin 51.88 %
Gross Profit Margin Total Ranking # 1772
Gross Profit In Millions $3.97
Y / Y Gross Profit Change -40.14 %
Seq. Gross Profit Change -4.82 %


Commenting Second Quarter 2026 Gross Profit Margin
Scilex Holding Company increased Gross Profit Margin through reduction in Cost of Sales and despite contraction in Gross Profit by -4.82 % and Revenue by -11.27 %. Gross Profit Margin in Q2 was 51.88 %, below company average.


Observing second quarter 2026 results within Biotechnology & Pharmaceuticals industry 30 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 1772, from total ranking in the previous quarter at 2022.
Learn about Gross Margin
SCLX's Gross Profit Margin second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 31
Healthcare Sector # 318
Overall # 1759

Gross Profit Margin Statistics
High Average Low
73.9 % 64.11 % 45.46 %
(Sep 30 2024)   (Dec 31 2025)


SCLX Gross Income Trends • More of SCLX's Profitabilty Ratios • SCLX Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
SCLX's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
SCLX's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for SCLX's Competitors
Gross Profit Margin Profit Margin for Scilex Holding's Suppliers
Gross Profit Margin Profit Margin for SCLX's Customers

You may also want to know
SCLX's Annual Growth Rates SCLX's Profitability Ratios SCLX's Asset Turnover Ratio SCLX's Dividend Growth
SCLX's Roe SCLX's Valuation Ratios SCLX's Financial Strength Ratios SCLX's Gross Profit Growth
SCLX's Roa SCLX's Inventory Turnover Ratio SCLX's Growth Rates SCLX's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginJun 30 2026 MRQ Gross ProfitJun 30 2026 MRQ Revenue
Immunitybio inc   99.42 %$ 50.942  Millions$ 51.240  Millions
Immunocore Holdings Plc  99.06 %$ 114.839  Millions$ 115.927  Millions
Biocryst Pharmaceuticals Inc   98.24 %$ 214.410  Millions$ 218.250  Millions
Neurocrine Biosciences Inc   97.58 %$ 935.800  Millions$ 959.000  Millions
Denali Therapeutics Inc   97.42 %$ 3.511  Millions$ 3.604  Millions
Exelixis Inc   96.71 %$ 608.033  Millions$ 628.690  Millions
Lenz Therapeutics Inc   94.90 %$ 5.206  Millions$ 5.486  Millions
Alpha Cognition Inc.  93.58 %$ 5.702  Millions$ 6.093  Millions
Tarsus Pharmaceuticals Inc   93.03 %$ 161.799  Millions$ 173.912  Millions
Ginkgo Bioworks Holdings Inc   91.47 %$ 18.437  Millions$ 20.156  Millions
Halozyme Therapeutics Inc   83.54 %$ 401.828  Millions$ 480.999  Millions
Gilead Sciences Inc   79.76 %$ 6,224.000  Millions$ 7,803.000  Millions
Pelthos Therapeutics Inc   76.86 %$ 11.993  Millions$ 15.603  Millions
Novavax inc   74.87 %$ 42.452  Millions$ 56.698  Millions
Vericel Corporation  72.82 %$ 56.402  Millions$ 77.457  Millions
Amgen Inc   72.04 %$ 7,243.000  Millions$ 10,054.000  Millions
Adaptive Biotechnologies Corporation  71.82 %$ 51.388  Millions$ 71.553  Millions
Coherus Oncology inc   70.35 %$ 10.065  Millions$ 14.307  Millions
Adma Biologics Inc   69.36 %$ 86.277  Millions$ 124.395  Millions
Bio techne Corp  65.82 %$ 211.394  Millions$ 321.192  Millions
Protalix Biotherapeutics inc   60.99 %$ 12.134  Millions$ 19.896  Millions
Elutia Inc   59.62 %$ 1.447  Millions$ 2.427  Millions
Pluri Inc   58.51 %$ 0.196  Millions$ 0.335  Millions
Xtant Medical Holdings Inc   57.88 %$ 13.330  Millions$ 23.031  Millions
Iovance Biotherapeutics inc   56.10 %$ 55.718  Millions$ 99.313  Millions
Autolus Therapeutics Plc  55.20 %$ 25.221  Millions$ 45.689  Millions
Repligen Corp  53.91 %$ 110.037  Millions$ 204.128  Millions
Twist Bioscience Corporation  52.76 %$ 62.454  Millions$ 118.376  Millions
Scilex Holding Company  51.88 %$ 3.965  Millions$ 7.642  Millions
Champions Oncology Inc   50.54 %$ 7.698  Millions$ 15.232  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.